Cat Allergy News and Research

RSS
NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia commences ToleroMune phase 3 trial in cat allergen-induced rhinoconjunctivitis

Circassia commences ToleroMune phase 3 trial in cat allergen-induced rhinoconjunctivitis

Advaxis, Karolinska Institutet enter collaboration to develop cat allergy vaccine

Advaxis, Karolinska Institutet enter collaboration to develop cat allergy vaccine

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia announces advancement in T-cell allergy vaccines development

Circassia announces advancement in T-cell allergy vaccines development

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Positive results from recently completed phase II clinical study of ToleroMune therapy announced

Positive results from recently completed phase II clinical study of ToleroMune therapy announced

30 percent of asthma in U.S.can be attributed to cat allergy

30 percent of asthma in U.S.can be attributed to cat allergy

Cells that might be able to suppres cat allergies

Cells that might be able to suppres cat allergies

New therapy for treating cat allergies looks promising

New therapy for treating cat allergies looks promising